CompletedPhase 4

Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation

Brazil34 participantsStarted 2012-07

Plain-language summary

The purpose of this study is to determine whether zolendronic acid, a third generation bisphosphonate, is effective in preventing bone loss in the first year after kidney transplantation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All adult kidney transplant recipients who were stable perioperative and able to return for regular follow-up Exclusion Criteria: * Glomerular filtration rate \< 30 ml/min/1.73m² one week after transplantation * Previous parathyroidectomy or diagnosis of adynamic bone disease (with bone biopsy)

What they're measuring

Differences in bone turnover

Timeframe: 1 year

Trial details

NCT IDNCT01675089

SponsorUniversity of Sao Paulo General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-07

View on ClinicalTrials.gov More Renal Osteodystrophy trials